SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
BURLINGAME, Calif., Sept. 20, 2017 -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will present at the 2017 Cantor Fitzgerald Global Healthcare Conference in New York City, New York. The presentation is scheduled for Wednesday, September 27, at 1:05 p.m. Eastern Time.
A webcast of the presentation will be available live and for 30 days following the event. The webcast may be accessed via the conference website and from the investor relations section of the Corvus website.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444, is a checkpoint inhibitor that is designed to disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with Genentech’s Tecentriq® (atezolizumab), an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For more information, visit: www.corvuspharma.com.
Tecentriq® (atezolizumab) is a registered trademark of Genentech.
Corvus Contact:
Guillermo Elias, PhD
Director, Business Development
Corvus Pharmaceuticals, Inc.
+1-650-889-4377
[email protected]
Media Contact:
Julie Normart
Pure Communications
+1-415-946-1087
[email protected]
